Talazoparib – Potent PARP Inhibitor for BRCA-Mutated Cancer

Talazoparib is a highly potent, innovative oral inhibitor of poly(ADP-ribose) polymerase (PARP) enzymes, specifically PARP-1 and PARP-2. The drug was developed for the targeted therapy of malignancies characterized by DNA repair defects, particularly locally advanced or metastatic breast cancer harboring germline (inherited) BRCA1 or BRCA2 mutations. The mechanism of action of talazoparib is dual: it not only selectively blocks the catalytic activity of PARP enzymes, preventing the repair of single-strand DNA breaks, but also possesses a unique capacity to robustly trap the PARP protein on damaged chromatin sites (the "PARP-trapping" phenomenon). This leads to the irreversible stalling of replication forks, the formation of lethal double-strand DNA breaks, and the subsequent induction of tumor cell apoptosis.

The primary clinical advantage of talazoparib lies in exploiting the principle of "synthetic lethality." In healthy somatic cells, where homologous recombination repair mechanisms are intact, DNA damage is successfully repaired, whereas in BRCA-mutated tumor cells, alternative repair pathways are absent, leading to selective cell death. Among all available PARP inhibitors, talazoparib exhibits the highest efficiency in trapping the PARP enzyme on DNA, which accounts for its potent antitumor activity at substantially lower therapeutic doses. The drug is rapidly absorbed following oral administration, exhibits linear pharmacokinetics, undergoes minimal hepatic metabolism, and is excreted predominantly unchanged by the kidneys.

The drug is administered orally. Prior to initiating therapy, confirmation of a deleterious germline BRCA mutation using a validated test is mandatory, and regular complete blood count monitoring is required throughout the course.